| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.47 | 6e-54 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.38 | 2e-29 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.37 | 2e-27 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.42 | 4e-20 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | 0.31 | 6e-20 |
| mRNA | tretinoin:carboplatin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.29 | 1e-17 |
| mRNA | ATRA | CTRPv2 | pan-cancer | AAC | 0.28 | 1e-16 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.29 | 3e-16 |
| mRNA | Sunitinib | CTRPv2 | pan-cancer | AAC | 0.27 | 1e-15 |
| mRNA | ATRA | GDSC1000 | pan-cancer | AAC | 0.26 | 4e-15 |